Direct-Acting Oral Anticoagulant Dabigatran as a Bridging Therapy while Optimizing Warfarin Dosage for Cardioembolic Stroke
The use of DOACs such as dabigatran as bridging therapy during optimization of OAC is feasible. Compared to heparin as bridging therapy, DOAC has the advantage of oral administration, lower cost, and possibly lower bleeding risks. This novel practice may be applicable in thrombosis in arterial and venous circulations, e.g., ischaemic stroke, deep venous thrombosis, pulmonary embolism.
Authors
- Narayanaswamy Venketasubramanian (ORCID: https://orcid.org/0000-0003-3593-6362)
- Leonard L.L. Yeo (ORCID: https://orcid.org/0000-0002-4249-0402)
- Yohanna Kusuma (ORCID: https://orcid.org/0000-0002-0946-3066)
- Bernard P.L. Chan
Institutions
- The Royal Melbourne Hospital (AU)
- Deakin University (AU)
- National University of Singapore (SG)
- Universitas Airlangga (ID)
- Raffles Institution (SG)
- National Brain Centre (ID)
- Melbourne Sexual Health Centre (AU)
Publication Details
- Journal
- Cerebrovascular Diseases Extra
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1159/000543301
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00